Pexelizumab
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized (from mouse) |
| Target | Complement component 5 |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| ATC code | None |
| ChemSpider | none |
| UNII |
CHZ6OLQ3UU  |
| (verify) | |
Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting[1] and angioplasty,[2][3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]
Current Status
Alexion, the developer of pexelizumab stopped development due to disappointing phase 3 results indicating the heart-attack drug is no better than placebo.[5]
References
- ↑ ClinicalTrials.gov: Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass
- ↑ ClinicalTrials.gov: Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction
- ↑ Testa, L; Van Gaal, WJ; Bhindi, R; Biondi-Zoccai, GG; Abbate, A; Agostoni, P; Porto, I; Andreotti, F; et al. (2008). "Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients". The Journal of thoracic and cardiovascular surgery 136 (4): 884–93. doi:10.1016/j.jtcvs.2007.12.062. PMID 18954626.
- ↑ Mathew, JP; Shernan, SK; White, WD; Fitch, JC; Chen, JC; Bell, L; Newman, MF (2004). "Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.". Stroke; a journal of cerebral circulation 35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID 15331798.
- ↑ Analysis: Alexion's pexelizumab fails
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.